Cannabidiol Studied as Potential Treatment for Cannabis Use Disorder
Abstinence from cannabis increased with cannabidiol 400mg, 800mg doses compared with placebo.
Addiction/dependence
FDA Requires Labeling Changes for Opioids to Include Information About Naloxone
The FDA has announced that it is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder to include new recommendations about naloxone to the prescribing information.
USPSTF Urges Primary Care Docs to Ask Adults About Drug Use
Evidence inadequate to assess benefits and harms of screening for unhealthy drug use in teens.
Unapproved Cannabidiol, Curcumin Injectables Marketed for Multiple Disorders Recalled
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
Aristada, Vivitrol Access Expanded During COVID-19 Pandemic
Alkermes has decided to expand the number of retail pharmacies and clinics where patients can receive access to Aristada (aripiprazole lauroxil) and Vivitrol (naltrexone extended-release injectable suspension).
E-Cigarette and Vaping-Associated Lung Injuries May Have Been Overlooked in the Past
Cases of e-cigarette or vaping product use–associated lung injury (EVALI) appear to have been overlooked in the past.
Physicians Report Low Interest in Opioid Use Disorder Meds
Few PCPs report obtaining buprenorphine waiver orprescribing buprenorphine, naltrexone for OUD.
DEA: 2020 Drugs of Abuse Resource Guide Now Available
The guide includes information on a drug’s origin, common street names, how it is abused, what effect it has on the mind and body, what the overdose effects are, and what its legal status is in the US.
Application for Digital Therapeutic Used to Curb Harmful Alcohol Consumption Submitted to FDA
Orexo has submitted an application to the Food and Drug Administration (FDA) for Vorvida® (OXD02), a digital therapy, to enable commercialization in the US for the treatment of bothersome or harmful alcohol consumption including diagnosed alcohol use disorder.
Evidence Lacking for Pharmacologic Therapy for Cannabis Use Disorder
Several drug classes including cannabinoids, SSRIs seem to be ineffective for cannabis use disorder
